PURPOSE OF REVIEW: Brown adipose tissue (BAT) is an emerging target to combat cardiometabolic disorders as it can take up substantial amounts of glucose and lipids from the circulation for heat production. This review focuses on new concepts in BAT physiology and discusses the need for new techniques to determine BAT activity in humans. RECENT FINDINGS: Mouse studies showed that BAT activation selectively increases oxidation of lipids over glucose, by recruiting fatty acids from intracellular triglycerides. To replenish these intracellular lipid stores, brown adipocytes take up both glucose and triglyceride-derived fatty acids, resulting in attenuation of dyslipidaemia, insulin resistance and atherosclerosis. Clinical studies identified the involvement of the β3-adrenergic receptor in BAT activation and demonstrated that human BAT activation also selectively increases lipid oxidation. Notably, insulin resistance during ageing or weight gain reduces the capacity of BAT to internalize glucose, without reducing fatty acid uptake or oxidative metabolism. SUMMARY: Preclinical studies established BAT as an important target to combat cardiometabolic disorders and elucidated underlying mechanisms whereas clinical studies identified therapeutic handles. Development of novel lipid-based PET-CT tracers and identification of translational biomarkers of BAT activity are required as alternatives to [F]fluorodeoxyglucose PET-CT to accelerate clinical development of BAT-activating therapeutic strategies.
PURPOSE OF REVIEW: Brown adipose tissue (BAT) is an emerging target to combat cardiometabolic disorders as it can take up substantial amounts of glucose and lipids from the circulation for heat production. This review focuses on new concepts in BAT physiology and discusses the need for new techniques to determine BAT activity in humans. RECENT FINDINGS:Mouse studies showed that BAT activation selectively increases oxidation of lipids over glucose, by recruiting fatty acids from intracellular triglycerides. To replenish these intracellular lipid stores, brown adipocytes take up both glucose and triglyceride-derived fatty acids, resulting in attenuation of dyslipidaemia, insulin resistance and atherosclerosis. Clinical studies identified the involvement of the β3-adrenergic receptor in BAT activation and demonstrated that human BAT activation also selectively increases lipid oxidation. Notably, insulin resistance during ageing or weight gain reduces the capacity of BAT to internalize glucose, without reducing fatty acid uptake or oxidative metabolism. SUMMARY: Preclinical studies established BAT as an important target to combat cardiometabolic disorders and elucidated underlying mechanisms whereas clinical studies identified therapeutic handles. Development of novel lipid-based PET-CT tracers and identification of translational biomarkers of BAT activity are required as alternatives to [F]fluorodeoxyglucose PET-CT to accelerate clinical development of BAT-activating therapeutic strategies.
Authors: Francisco M Acosta; Jörn Berchem; Borja Martinez-Tellez; Guillermo Sanchez-Delgado; Juan M A Alcantara; Lourdes Ortiz-Alvarez; Takafumi Hamaoka; Jonatan R Ruiz Journal: Mol Imaging Biol Date: 2019-04 Impact factor: 3.488
Authors: L L Blauw; R Noordam; S Trompet; J F P Berbée; F R Rosendaal; D van Heemst; K W van Dijk; D O Mook-Kanamori; R de Mutsert; P C N Rensen Journal: Int J Obes (Lond) Date: 2017-06-19 Impact factor: 5.095
Authors: L Ortiz-Alvarez; F M Acosta; J R Ruiz; B Martinez-Tellez; H Xu; G Sanchez-Delgado; R Vilchez-Vargas; A Link; J Plaza-Díaz; J M Llamas; A Gil; I Labayen; P C N Rensen Journal: J Endocrinol Invest Date: 2022-10-15 Impact factor: 5.467
Authors: Guillermo Sanchez-Delgado; Borja Martinez-Tellez; Yolanda Garcia-Rivero; Francisco M Acosta; Juan M A Alcantara; Francisco J Amaro-Gahete; Jose M Llamas-Elvira; Luis Gracia-Marco; Jonatan R Ruiz Journal: Int J Obes (Lond) Date: 2018-12-05 Impact factor: 5.095
Authors: Hana Malinská; Martina Hüttl; Denisa Miklánková; Jaroslava Trnovská; Iveta Zapletalová; Martin Poruba; Irena Marková Journal: Int J Mol Sci Date: 2021-04-26 Impact factor: 5.923
Authors: Lisanne L Blauw; N Ahmad Aziz; Martijn R Tannemaat; C Alexander Blauw; Anton J de Craen; Hanno Pijl; Patrick C N Rensen Journal: BMJ Open Diabetes Res Care Date: 2017-02-20
Authors: Alexander Bartelt; Clara John; Nicola Schaltenberg; Jimmy F P Berbée; Anna Worthmann; M Lisa Cherradi; Christian Schlein; Julia Piepenburg; Mariëtte R Boon; Franz Rinninger; Markus Heine; Klaus Toedter; Andreas Niemeier; Stefan K Nilsson; Markus Fischer; Sander L Wijers; Wouter van Marken Lichtenbelt; Ludger Scheja; Patrick C N Rensen; Joerg Heeren Journal: Nat Commun Date: 2017-04-19 Impact factor: 14.919
Authors: Guillermo Sanchez-Delgado; Borja Martinez-Tellez; Yolanda Garcia-Rivero; Juan M A Alcantara; Francisco M Acosta; Francisco J Amaro-Gahete; Jose M Llamas-Elvira; Jonatan R Ruiz Journal: Front Physiol Date: 2018-11-16 Impact factor: 4.566
Authors: Maaike Schilperoort; Andrea D van Dam; Geerte Hoeke; Irina G Shabalina; Anthony Okolo; Aylin C Hanyaloglu; Lea H Dib; Isabel M Mol; Natarin Caengprasath; Yi-Wah Chan; Sami Damak; Anne Reifel Miller; Tamer Coskun; Bharat Shimpukade; Trond Ulven; Sander Kooijman; Patrick Cn Rensen; Mark Christian Journal: EMBO Mol Med Date: 2018-03 Impact factor: 12.137